Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells

Molecular Biology Reports

Volumn 38, Issue 6, 2011, Pages 3679-3688

  Wisniewska Jarosinska, Maria ^a   Sliwinski, Tomasz ^b   Kasznicki, Jacek ^a   Kaczmarczyk, Dariusz ^a   Krupa, Renata ^b   Bloch, Karolina ^b   Drzewoski, Jozef ^a   Chojnacki, Jan ^a   Blasiak, Janusz ^b   Morawiec Sztandera, Alina ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Capecitabine; Cell cycle; DNA damage; DNA repair; Head and neck cancer

Indexed keywords

ALPHA (4 PYRIDIL 1 OXIDE) N TERT BUTYLNITRONE; CAPECITABINE; N TERT BUTYL ALPHA PHENYLNITRONE; NITRONE DERIVATIVE; PLASMID DNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA DETERMINATION; DNA ISOLATION; DRUG STRUCTURE; FLOW CYTOMETRY; GENOTOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE;

CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; DNA REPAIR ENZYMES; DNA, CIRCULAR; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES; MUTAGENS; NEOPLASMS, SQUAMOUS CELL; PLASMIDS; SPIN LABELS; TIME FACTORS;

EID: 80052465071     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0482-7     Document Type: Article

References (29)

1. Colevas AD, Amrein PC, Gomolin H et al (2001) A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer 92:326-331. (Pubitemid 32664438)
2. Bazarbashi S, Abdelsalam M, Amin T et al (2008) Phase II trial of neo adjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus. Chemotherapy 54:315-322.
3. Malet-Martino M, Martino R (2002) Clinical studies of three oral pro drugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7:288-323. (Pubitemid 34919955)
4. Grem JL (2000) 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investig New Drugs 18:31-299.
5. Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5:2672-2673. (Pubitemid 29493937)
6. Fuse N, Doi T, Ohtsu A et al (2008) Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 13:144-149. (Pubitemid 351668172)
7. Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281. (Pubitemid 28342121)
8. Comella P (2007) A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag 3:421-431. (Pubitemid 47214982)
9. Ooyama A, Oka T, Zhao HY et al (2008) Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenograft. Cancer Lett 267:26-36.
10. Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23-44. (Pubitemid 40347299)
11. Mackean M, Planting A, Twelves C et al (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985. (Pubitemid 28417417)
12. Pivot X, Chamorey E, Guardiola E et al (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14:1578-1586. (Pubitemid 37304616)
13. Diaz-Rubio E, Evans TR, Tabernero J et al (2002) Capecitabine (Xeloda) in combination with oxaliplatin: a phase I dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 13:558-565. (Pubitemid 34461139)
14. Tang p, Oza A, Townsley C et al (2007) Phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. J Clin Oncol 25:3576.
15. Pronk LC, Vasey P, Sparreboom A et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22-29. (Pubitemid 30352712)
16. Villalona-Calero MA, Weiss GR, Burris HA et al (1999) Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 17:1915-1925. (Pubitemid 29269265)
17. Chua D, Wei WI, Sham JS et al (2008) Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 38:244-249. (Pubitemid 351583987)
18. Alexandre J, Kahatt C, Bertheault-Cvitkovic F et al (2007) A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs 25:453-462. (Pubitemid 47222915)
19. Becerra BC, Verma UN, Tran HT et al (2008) Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol 31:219-225.
20. Kainthla R, Zewail-Foote M (2008) Oxidative DNA damage following photoexcitation of daunomycin: direct role of oxygen. J Photochem Photobiol A 198:200-204.
21. Singh NP, McCoy T, Tice RR et al (1998) A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 175:184-192.
22. Klaude M, Eriksson S, Nygren J et al (1996) The comet assay: mechanisms and technical considerations. Mutat Res 12:89-96. (Pubitemid 26225011)
23. Blasiak J, Gloc E, Drzewoski J et al (2003) Free radicals scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutat Res 535:25-34. (Pubitemid 36120758)
24. Singh NP, Stephens RE (1997) Microgel electrophoresis: sensitivity, mechanisms and DNA electro stretching. Mutat Res 383:167-175.
25. Tice RR, Agurell E, Anderson D et al (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221. (Pubitemid 30196665)
26. Petronzelli F, Riccio A, Markham GD et al (2000) Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J Cell Physiol 185:473-480.
27. Luo Y, Walla M, Wyatt MD (2008) Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair 7:162-169.
28. Welsh SJ, Hobbs S, Aherne GW (2003) Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. Eur J Cancer 39:378-387. (Pubitemid 36140057)
29. Rustum YM (2004) Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9:2467-2473.